Northern Trust
KTTA icon

Northern Trust’s Pasithea Therapeutics KTTA Stock Holding History

Northern Trust’s Portfolio KTTA Stock Details KTTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$14.4K Sell
19,372
-8,718
-31% -$7.29K ﹤0.01% 4355
2025
Q4 		$36.2K Buy
+28,090
New +$24.7K ﹤0.01% 4334
2024
Q1 		– Sell
-2,354
Closed -$17.4K – 4451
2023
Q4 		$17.4K Buy
+2,354
New +$17.5K ﹤0.01% 4379

Other funds holding KTTA

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $273M AUM
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
CCC
Cable Car Capital San Francisco, California $289M AUM 26.33% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $549M AUM 32.58% 1-Year Est. Return
PAP
Persistent Asset Partners Hong Kong $268M AUM 158.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust's KTTA Position: Q1 2026 in Review

Northern Trust reduced its Pasithea Therapeutics (KTTA) stake by 31% in Q1 2026, selling an estimated $7.29K and leaving 19,372 shares worth $14.4K. The position accounts for ﹤0.01% of the portfolio, ranked #4355.

Northern Trust first reported a position in KTTA in Q4 2023 and has held it in 3 quarters since. The position peaked at $36.2K in Q4 2025. 21 funds tracked by Wall St. Rank hold KTTA as of Q1 2026.

  • Northern Trust held 19,372 shares of Pasithea Therapeutics worth $14.4K as of Q1 2026.
  • Northern Trust sold 8,718 Pasithea Therapeutics shares in Q1 2026, an estimated $7.29K.
  • Pasithea Therapeutics made up ﹤0.01% of Northern Trust's portfolio in Q1 2026, its #4355 holding.
  • Northern Trust first reported a position in Pasithea Therapeutics in Q4 2023 and has held it in 3 quarters since.
  • Northern Trust's Pasithea Therapeutics position peaked at $36.2K in Q4 2025.
  • 21 funds tracked by Wall St. Rank held Pasithea Therapeutics as of Q1 2026.

Based on Northern Trust's 13F filing for Q1 2026, filed 14 May 2026.